Thrombolytic and newer mechanical device treatment for acute ischemic stroke

Research output: Contribution to journalReview articlepeer-review

9 Scopus citations


For 8 years, only intravenous tissue plasminogen activator was approved by the US FDA for acute stroke treatment. The US FDA has now cleared the Merci® Retriever (Concentric Medical, Inc.), a corkscrew-like device attached to a catheter, for the removal of clots causing ischemic strokes. Since the clearance was based on nonrandomized treatment trials, practitioners must scrutinize available data describing effects of the device on recanalization of the vessel, outcomes and important adverse events, such as symptomatic intracranial hemorrhage. This article reviews the study findings that are likely to contribute to current treatment decisions.

Original languageEnglish (US)
Pages (from-to)1099-1105
Number of pages7
JournalExpert Review of Neurotherapeutics
Issue number7
StatePublished - 2006


  • Acute stroke treatment
  • Device
  • Intra-arterial
  • Mechanical thrombolysis
  • Merci Retriever
  • Stroke
  • Tissue plasminogen activator

ASJC Scopus subject areas

  • Neuroscience(all)
  • Clinical Neurology
  • Pharmacology (medical)


Dive into the research topics of 'Thrombolytic and newer mechanical device treatment for acute ischemic stroke'. Together they form a unique fingerprint.

Cite this